Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By Ockham Research (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Philips-Van Heusen Falls on Dingy Outlook

% of readers think this story is Fact. Add your two cents.


On Monday evening, clothing maker Philips-Van Heusen (PVH) reported fiscal first quarter results that topped analysts’ expectations when excluding costs associated with their acquisition of Tommy Hilfiger.  For the quarter the company earned 83 cents per share, ahead of the 79 cents per share analysts had anticipated.  Sales were strong as well rising 11% to $619 million boosted by 13% growth in the Calvin Klein brand.  Shares slipped as much as 5% in early morning trading but losses have subsided somewhat to only about 3% as of the time of writing.

For the quarter ahead, PVH management expects 50 to 52 cents per share (again excluding nonrecurring costs), and they said weaker seasonal business trends and higher base share count is expected to impact earnings by 12 cents per share.  Most analysts were not expecting the Tommy acquisition to close until the end of the second quarter, but as it turns out that the share dilution will be accounted for over the course of the entire quarter.  Analyst estimates were calling for 70 cents per share, so the outlook for the next quarter is weaker than expected even after adjusting for the 12 cents impact.  Furthermore, sales forecasts are for $1.08B to $1.10B including $520 million from Tommy Hilfiger.  Analysts’ revenue estimates for the second quarter (most of which exclude Tommy) called for $714 million, so the new outlook is again disappointing.

It is not exactly clear how comparable guidance is to analysts’ estimates for the coming quarter because of the quicker than expected closing of the Tommy Hilfiger acquisition.  However, full year estimates and guidance should match up reasonably well.  Updated guidance for the year is $3.55 to $3.65 in earnings per share on sales of $4.35 billion to $4.40 billion.  Interestingly, this guidance came in stronger than expected for sales, but earnings per share are a little light in light of Wall Street’s expectations.

As of our most recent report, we held that PVH was Overvalued at a price of about $53 per share (as of the report dated 5/22/2010).  Based on the historically normal ranges of price-to-cash earnings and price-to-sales, we have a rationally expected price range of $41 to $56 per share.  Obviously, fundamentals are growing following the acquisition of Tommy but so is the number of shares outstanding.  With Philips-Van Heusen estimating there will be 71.5 million shares outstanding, the deal represents a nearly 38% increase in share count.  We may have a more favorable view of PVH once all of those shares are absorbed, but as of right now we think there are much more appealing value stocks available.

Read the original story at Ockham Research



Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.


LION'S MANE PRODUCT


Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules


Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.



Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.


Report abuse

    Comments

    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    MOST RECENT
    Load more ...

    SignUp

    Login